Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Prostatic Neoplasm: early-phase trial registry

2 of 10 indexed Prostatic Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 2 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Prostatic Neoplasm: 10 US clinical trials tracked, 2 recruiting.

Prostatic Neoplasm is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Schiffler Cancer Center, running 1 of these trials.

Enrollment posture brief

Registry condition prostatic-neoplasm

OPEN 2 | RECR 20% | LATE 1 | EARLY 5 | RANK #1724 | SPON 1

Nearest open-share peer: Acral Lentiginous Melanoma (20% recruiting · 5 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%Prostatic Neoplasm (this)20%
Open-enrollment share among volume-matched conditions near Prostatic Neoplasm

Prostatic Neoplasm lists 2 open slots (20% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Prostatic Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Prostatic Neoplasm is recruiting below its size-band peers.

    2 of 10 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Prostatic Neoplasm trials is spread across many organizations.

    Schiffler Cancer Center accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Typical Prostatic Neoplasm enrolment sits around 150 participants.

    Median target enrolment is 150 among the 10 trials that report a genuine target (sentinel values excluded). 3 of those (30%) plan for fewer than 100 participants.

  4. Prostatic Neoplasm research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23Phase 31

Open and recent trials

10 total, page 1 of 1

RECRUITING 400 participants

Prostate Cancer Genetic Risk Evaluation and Screening Study

Massachusetts General Hospital

NCT05129605

RECRUITING NA 150 participants

Investigation of Impact of AI on Prostate Cancer Workflow

Case Comprehensive Cancer Center

NCT07084779

ACTIVE NOT RECRUITING Phase 2 49 participants

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Novartis Pharmaceuticals

NCT05849298

ACTIVE NOT RECRUITING Phase 1 30 participants

Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness

University of Maryland, Baltimore

NCT05968144

COMPLETED NA 600 participants

Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

Wake Forest University Health Sciences

NCT03935282

COMPLETED NA 403 participants

Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors

University of Minnesota

NCT03343093

COMPLETED Phase 3 319 participants

Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial

Schiffler Cancer Center

NCT00247312

COMPLETED Phase 2 131 participants

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Janssen Biotech

NCT01314118

COMPLETED Phase 2 120 participants

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

Progenics Pharmaceuticals

NCT03939689

COMPLETED Phase 1 72 participants

Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer

Mayo Clinic

NCT00956228

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 1

Named interventions

Most-linked intervention names on Prostatic Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Pd-103 Radiation
1 trials
radioimmuniguided intenstiy modulated radiotherapy Radiation
1 trials
AH-HA Tool in the EPIC EHR Other
1 trials
abiraterone acetate in combination with prednisone Drug
1 trials
I-131-1095 Drug
1 trials
Restore Rehabilitation Program Behavioral
1 trials
Dietary recommendations Behavioral
1 trials
Piflufolastat F 18 Drug
1 trials

US sites by state

Facility locations filed on Prostatic Neoplasm trials. A trial with sites in several states counts in each.

Pennsylvania 3 trials
Maryland 3 trials
Iowa 3 trials
Washington 2 trials
Virginia 2 trials
Texas 2 trials
South Carolina 2 trials
New York 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Prostatic Neoplasm page

10 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostatic Neoplasm condition card totals 10 registered trials; most-linked intervention Pd-103; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.